Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). BetterLife Pharma's share price for the quarter that ended in Oct. 2023 was C$0.065. BetterLife Pharma's Shares Outstanding (EOP) for the quarter that ended in Oct. 2023 was 113.83 Mil. Therefore, BetterLife Pharma's market cap for the quarter that ended in Oct. 2023 was C$7.40 Mil.
BetterLife Pharma's quarterly market cap
declined
from Apr. 2023 (C$9.24 Mil) to Jul. 2023 (C$7.76 Mil) and
declined
from Jul. 2023 (C$7.76 Mil) to Oct. 2023 (C$7.40 Mil).
BetterLife Pharma's annual market cap
declined
from Jan. 2021 (C$69.97 Mil) to Jan. 2022 (C$17.47 Mil) and
declined
from Jan. 2022 (C$17.47 Mil) to Jan. 2023 (C$13.52 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. BetterLife Pharma's Enterprise Value for Today is C$15.17 Mil.
BetterLife Pharma Market Cap Historical Data
The historical data trend for BetterLife Pharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of BetterLife Pharma's Market Cap
For the Biotechnology subindustry, BetterLife Pharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BetterLife Pharma's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BetterLife Pharma's Market Cap distribution charts can be found below:
* The bar in red indicates where BetterLife Pharma's Market Cap falls into.
BetterLife Pharma Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
BetterLife Pharma's Market Cap for the fiscal year that ended in Jan. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BetterLife Pharma (XCNQ:BETR) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
BetterLife Pharma Market Cap Related Terms
Thank you for viewing the detailed overview of BetterLife Pharma's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
BetterLife Pharma (XCNQ:BETR) Business Description
BetterLife Pharma Inc a biotechnology company, engages in the development and commercialization of psychedelic products for the treatment of mental disorders in Canada, the United States, Australia, and European Union. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections, such as coronavirus disease and human papillomavirus, and/or to directly inhibit tumors to treat various types of cancer.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XCNQ:BETR has been successfully added to your 